Zhu Yi

Early Life and Education

Zhu Yi began his career in the field of education. He taught immunology and microbiology at West China University of Medical Sciences, laying the groundwork for his future ventures in pharmaceuticals. He furthered his education by obtaining a Master's in biology from Fudan University and a doctorate in management from Sichuan University.

Rise to Success

In 1996, Zhu Yi founded Biokin Pharmaceuticals. Under his leadership, the company developed into a modern bio-pharmaceutical enterprise. Zhu's focus has been on the integration of research and development, manufacturing, and marketing of chemical drugs and biologics. Zhu Yi's vision drove the company's diverse product range, including medications for children, cardiovascular drugs, anesthetics, and chronic disease treatments.

Key Business Strategies

Key business strategies include the company's 2023 IPO in Shanghai, which raised $136 million. Biokin's U.S. subsidiary, SystImmune, signed an $8.4 billion deal with Bristol Myers Squibb to co-develop and commercialize a potential cancer treatment worldwide. The company's expansion included seeking a Hong Kong IPO since 2024.

Philanthropy

Details on Zhu Yi's specific philanthropic endeavors are not readily available in the search results. Further research would be needed to determine specific initiatives and amounts.